COVID-19：アビガン､３８か国に無償供与：25EU,6Asia,5MiddleEast(動画）：
COVID-19: Avigan Granted to 38 Countries: 25EU, 6Asia, 5MiddleEast：
COVID-19：Avigan授予38个国家/地区：25EU，6亚洲，5中东
日本政府：
供与は、総額１００万ドル（約１億１０００万円）からなる政府の緊急無償資金協力の枠組みで実施される。
輸送は国連機関が担う。
手続きが完了した国から、アビガン順次発送する。
対象国には投与による効果などデータの提供を求め、日本の知見を高めることに活用する。
茂木外相：
治療効果があると、多くの事例が出てきている。
臨床研究を日本はもちろん、国際的にも拡大していきたいと述べた。
厚生労働省：
アビガン承認に向け、研究参加の手引をまとめ、２７日付で全国の医療機関に通知した。
多くの臨床データを早急に集め、分析を加速させる。
すでに約１１００の医療機関が研究に参加し、２０００人以上に投与済み。
研究目的：アビガン使用
医療機関/倫理審査委員会の事前承認
患者の同意
厚労省研究班へのデータ提供
読売新聞オンライン
https://www.yomiuri.co.jp/politics/20200428-OYT1T50212/
Japan to offer anti-flu drug Avigan to 38 countries as early as this week
APR 29, 2020
Japan will begin providing the anti-flu drug Avigan for free to 38 countries
as early as this week for treating patients with the new coronavirus, according to Foreign Minister Toshimitsu Motegi.
At a news conference Tuesday, Motegi also said over 70 countries,
including the 38, have made requests for Avigan to Japan, which has decided to offer a $1 million grant to the United Nations Office for Project Services to buy and distribute the drug, also known as favipiravir, to countries that want it.
“I’ve heard that (the U.N. agency) is arranging to start transporting the drug around the holidays after procedures have been completed,”
Motegi told the news conference, referring to the last five days of the Golden Week holidays from Saturday through next Wednesday.
Among the 38 nations are
- 25 European countries, mostly from Eastern Europe,
- six in Asia including the Philippines and Malaysia,
- five in the Middle East such as Kuwait and two from other regions,
Motegi said
Japan will be provided with data obtained from clinical tests on COVID-19 patients that will be conducted in the recipient countries using the drug, which was developed by a group firm of Fujifilm Holdings Corp.
The Japan Times
https://www.japantimes.co.jp/news/2020/04/29/national/japan-avigan-drug-38-countries/#.XqowR0FcWEd